EQS-Adhoc

Kuros Biosurgery Holding Ltd. closes merger with Cytos Biotechnology Ltd. which is renamed Kuros Biosciences Ltd - Seite 2

tested in large, controlled Phase 2b clinical trials demonstrating efficacy
by meeting the studies' primary endpoints. KUR-111 and KUR-113 share the
same biologically active agents and have been tested in clinical trials
involving over 380 patients to date exhibiting an excellent safety profile.

Kuros (formerly known as Kuros Biosurgery Holding Ltd.) announced in
November 2015 the completion of a financing of over CHF20 million that the
company expects to provide adequate financing to bring KUR-023 to market in
both Europe and the US. Moreover, this financing will allow the company to
prepare for a Phase 3 study with its lead product candidate for bone
healing, KUR-111.

In 2015, Kuros (under the name Cytos Biotechnology Ltd.) entered into two
exclusive license agreements in different fields with pharmaceutical
partners namely (i) an exclusive license agreement granting Arbutus
Biopharma Corp.(NASDAQ: ABUS) (formally known as OnCore Biopharma) access
to Kuros' clinically validated virus -like particle (VLP) platform for
use in the treatment and prevention of hepatitis B viral
infections and (ii) an exclusive license agreement in the field of oncology
granting Checkmate Pharmaceuticals LLC exclusive access to Kuros'
clinically validated product candidate CYT003 as well as its VLP platform
and to technology related to oligonucleotide synthesis.

For both collaborations, Kuros may receive development milestones and may
receive up to double digit royalties on net sales from successfully
developed products.

For further information, please contact:

Kuros Biosciences Ltd.
Harry Welten, MBA
Chief Financial Officer
Tel: [phone]
E-mail: [e-mail]

Didier Cowling
Chief Executive Officer
Tel: [phone]
E-mail: [e-mail]

For Media Enquires:
Citigate Dewe Rogerson
David Dible, Sylvie Berrebi
[e-mail]
[phone]

Legal Notice:

This media release is not an offer to sell, or a solicitation of an offer
to purchase, any securities of Kuros Biosciences Ltd (formerly Cytos
Biotechnology Ltd.) nor shall it or any part of it form the basis of, or be
relied on in connection with any contract or investment decision. This
announcement is not for publication or distribution (directly or
indirectly) in or to the United States, Canada, Australia, Japan or any
other jurisdiction in which such distribution might be unlawful. This media
release is no listing or offering prospectus or related document. The
shares of Kuros Biosciences Ltd (formerly Cytos Biotechnology Ltd.) are
only listed at SIX Swiss Exchange, Switzerland, and are not and will not be
registered in any other jurisdiction, including the countries mentioned in